OpenAI's GPT-Rosalind agents suggest a drug discovery lead; OpenAI reportedly acquires Orchestra Bio

OpenAI says its GPT-Rosalind agents worked with PerturbAI and Scripps Research to connect results from millions of mouse brain cells with scientific literature in 32 minutes. The agents suggested testing whether restoring cholesterol transport could protect neurons after disruption of DCTN1, a gene linked to Perry syndrome. A separate post reports that OpenAI acquired Orchestra Bio, a drug-development project-management AI company, for an undisclosed amount. Another user says biological validation and data generation remain bottlenecks.